ICR cancer drug NXP800 to enter Phase I trials
The investigational drug targets the HSF1 pathway
Read More
Tag: Institute for Cancer Research
Researchers identify new drug class with potential in BRCA-mutated tumours
POLQ inhibitors could be used to kill PARP inhibitor-resistant cancer cells
Read More
PARP inhibitors could exploit weaknesses in a range of cancers
Drug type could offer a new approach to treating a number of cancers with PBRM1 mutations
Read More
ICR urges change as NICE rejects Keytruda plus chemotherapy
Keytruda backed for monotherapy treatment but combination therapy rejected
Read More
New drug shows potential for treating childhood neuroblastoma
Drug is ready to progress into clinical trials after passing initial safety test
Read More
Monte Rosa Therapeutics raises $96m to develop protein-degrading molecules
ICR and Cancer Research UK spinout closes Series B financing
Read More
ICR study combines precision medicines to treat drug-resistant cancers
Researchers found combination treatment showed promise against a range of cancer types
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
